R&D Solutions
for Pharmacovigilance

Achieve pharmacovigilance with less pain and more efficiency

Get started

We provide drug safety data and literature monitoring solutions to help you maintain patient safety and compliance with less pain

Literature monitoring for pharmacovigilance can be painful. Staff are burdened with challenges such as ineffective search, manual workload, and GxP certification concerns. Companies must streamline decentralized processes and information management, access key data sources, and automate detection of safety signals.

How we help
We are a global leader in scientific data and analytics, offering comprehensive drug safety data sources and extensive experience alleviating challenges with pharmacovigilance processes. Our pharmacovigilance solutions — QUOSA PV, Embase and PharmaPendium — are used by practitioners to achieve pharmacovigilance with less pain and more efficiency.

We help our customers:

  • Quickly detect adverse event information across various types of scientific literature
  • Automate and centralize information monitoring and triage with detailed audit trails
  • Use more effective information search strategies

Ready to take the next step?
Contact us

  • Generate audit-ready reports
  • Track progress and manage workload of literature review staff members
  • Access FDA/EMA drug approval and comparative drug safety data

Elsevier's R&D Solutions - Pharma & Life Sciences Solution Finder

Answer a few questions to see which of our pharma & life sciences solutions can help you. From drug discovery to post-market, we offer solutions that can help you drive commercial success and manage risk.
Find the right solutions for your needs

Customer stories

Thousands of pharmacovigilance, drug safety and information practitioners rely on our solutions.

Donna Sees, Information Consultant with PharmIntell Consulting, discusses post-market surveillance best practices for medical device companies and how QUOSA provides reliable and efficient literature monitoring and triage.

Read the customer story (PDF, 521kb)

Donna Sees' customer story - Elsevier R&D Solutions Pharma & Life Sciences

Customer story - Elsevier R&D Solutions Pharma & Life Sciences

Missing adverse events can lead to serious consequences. When a top pharma firm received a regulatory warning letter, they turned to Elsevier's Professional Services team to implement a scalable scientific literature monitoring and triage strategy.

Read the customer story (PDF, 540kb)

Elsevier's R&D Solutions for Pharmacovigilance


Promote efficiency and organizational compliance by centralizing the discovery of adverse event information and automating information monitoring and triage in a scalable environment.

Learn more about QUOSA PV


Make more informed drug development decisions on safety and efficacy, risk assessments and mitigation, and study designs by providing researchers with searchable FDA/EMA drug approval documents and comparative drug safety data.
Learn more about PharmaPendium


Improve literature monitoring for adverse events with the world’s most comprehensive biomedical literature database.
Learn more about Embase

Professional Services

Streamline literature monitoring for adverse events by validating search strategies and implementing solutions for literature triage and review.  
Learn more about Professional Services

Ideas and insights for industry professionals

Five ways to make literature monitoring more comprehensive and manageable

White Paper - R&D Solutions | Elsevier

Due to recent regulatory changes and the continued deluge of data, information, and research, biomedical literature reviews are becoming much more time consuming and difficult. Learn five ways to make it more manageable.
Read the white paper

A practical guide to end-to-end pharmacovigilance

A Practical Guide to End-To-End Pharmacovigilance . - R&D Solutions | Elsevier

In response to new drug safety regulations that require PV teams to cover the full product life cycle, we present a practical guide to end-to-end pharmacovigilance.  

Read the Pharmacovigilance Guide